September 15th, 2019

A full text version of this article is available.
To access article obtain online access here or login
Anti-Müllerian Hormone and Inhibin B as Predictive Factors of Pregnancy Outcome in Women with Polycystic Ovary Syndrome: A Preliminary Report
Authors:  Monika Szafarowska, M.D., Ph.D., Artur Rogowski, M.D., Ph.D., Agnieszka Segiet, M.D., and Małgorzata Jerzak, M.D., Ph.D.
  OBJECTIVE: To assess the importance of anti-Müllerian hormone (AMH) and inhibin B as predictors of pregnancy achievement and success rates in polycystic ovary syndrome (PCOS) patients.

STUDY DESIGN: The study group included 44 infertile PCOS women (aged 25–44 years), and the control group consisted of 20 fertile women. Among PCOS patients 7 (15.9%) had primary infertility and 37 (84.1%) were women with a history of recurrent pregnancy loss.

RESULTS: In the light of the obtained results, inhibin B is a good predictor of clinical pregnancy in the group of PCOS women (p=0.002). For the cutoff value of 80.5 pg/mL, the specificity of inhibin B level ≥80.5 pg/mL as a clinical pregnancy predictor is 77.8%, with the predictor sensitivity of 75.0%. Moreover, our results suggest that AMH is a good predictor of miscarriage in the group of women who achieved pregnancy (p=0.002). For the cutoff value of 6.1 ng/mL, the specificity of AMH level ≥6.1 ng/mL as a miscarriage predictor is 100.0%, with the predictor sensitivity of 76.2%.

CONCLUSION: It seems that AMH and inhibin B levels may be related to pregnancy outcome in PCOS women.
Keywords:  anti-Müllerian hormone, assisted reproductive technologies, infertility, inhibin B, polycystic ovary syndrome, recurrent pregnancy loss
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from